Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 66

Results For "Bill"

683 News Found

Brooks announces new investments to build an integrated carbapenem business
News | July 15, 2021

Brooks announces new investments to build an integrated carbapenem business

SteriScience will infuse an additional amount of Rs. 74.5 crore, making a total investment commitment of Rs. 114.5 crore in BSL


Marksans Pharma shareholders vote for warrants worth Rs. 365 Cr
News | July 11, 2021

Marksans Pharma shareholders vote for warrants worth Rs. 365 Cr

The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant


RDIF and Morepen announce production of test batch of Sputnik V
News | July 08, 2021

RDIF and Morepen announce production of test batch of Sputnik V

The first batch will be shipped to the Gamaleya Center for the quality control


Panacea Biotec gets license to produce Sputnik V vaccine at Baddi
News | July 05, 2021

Panacea Biotec gets license to produce Sputnik V vaccine at Baddi

The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli in India


Lupin Launches Emtricitabine and Tenofovir Disoproxil Fumarate Tablets in the US
News | June 27, 2021

Lupin Launches Emtricitabine and Tenofovir Disoproxil Fumarate Tablets in the US

It is also used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.


Glenmark receives ANDA tentative approval for Nintedanib Capsules
News | June 26, 2021

Glenmark receives ANDA tentative approval for Nintedanib Capsules

According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion


Poxel and Sumitomo Dainippon gets TWYMEEG approval
News | June 25, 2021

Poxel and Sumitomo Dainippon gets TWYMEEG approval

The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies


Lupin receives U.S. FDA approval for HIV-1 drug
Pharma | June 08, 2021

Lupin receives U.S. FDA approval for HIV-1 drug

Emtricitabine and Tenofovir Disoproxil Fumarate tablets had estimated annual sales of US $2.1 billion in the U.S. according to IQVIA MAT March 2021


Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application
News | June 03, 2021

Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application

Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).


Progress on new ventures key for Aurobindo Pharma: ICICI Securities
News | June 02, 2021

Progress on new ventures key for Aurobindo Pharma: ICICI Securities

Aurobindo has one of the most enduring generics ecosystems among peers